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Phaeochromocytoma is a rare condition that provides a diagnostic challenge as a result of its variable
presentation. Treatment of metastatic malignant phaeochromocytoma is also not well defined owing to
its rarity. We present four such cases and a review of the literature. The database of the Singapore Cancer
Registry was used to trace all cases of metastatic malignant phaeochromocytoma from 1984 to 2004, and
the case records were then reviewed retrospectively. There were four patients with metastatic malignant
phaeochromocytoma seen in Singapore in the last 20 years. Their variable clinical courses were reviewed
and compared with current knowledge and overseas experience in the literature. We further discuss the
difficulties in diagnosis, and the dilemma in appropriate management of such cases. Phaeochromocytoma
remains a commonly missed diagnosis unless a high index of suspicion is maintained. Malignant
phaeochromocytoma has a variable clinical course. There is a place for radical surgery if this can render
the patient free of gross disease, or when it can achieve symptom control for palliation and improvement
in quality of life. In the metastatic context, debulking surgery does not appear to be of curative benefit,
although it may be undertaken for good palliation. [Asian J Surg 2006;29(4):294–302]
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Introduction
Phaeochromocytomas are rare tumours, occurring in less
than five per million of the general population,1 and
affecting less than 1% of the hypertensive population.2
Malignant forms of the condition are even rarer, forming
10–25% of all phaeochromocytomas, with a 5-year survival
rate of 44% reported.3
Phaeochromocytoma is a medically challenging con-
dition as it is potentially lethal if untreated and associated
with very high morbidity if unsuspected, yet it can be rela-
tively easily determined and localized if the diagnosis is
made correctly. The management of malignant forms of
the condition that manifest with local invasion or distant
metastases is less straightforward given its rarity and
remains controversial at the present time.
We present a case series of four patients with metasta-
tic malignant phaeochromocytoma and illustrate their
highly variable clinical courses and outcomes. We go on
to compare our Singaporean experience against the cur-
rent literature with respect to difficulties in arriving at the
diagnosis as well as the role of surgery and other adjunc-
tive treatment modalities in the optimal management of
such patients.
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Patients and methods
All cases of metastatic malignant phaeochromocytoma 
in Singapore in the last 20 years from 1984 to 2004 were
identified through a search of the database maintained by
the Singapore Cancer Registry. Their medical records
were reviewed with particular attention paid to intervention
at a given stage and the disease outcome. Four cases were
identified. They are presented below and summarized in
the Table.
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Table. Summary of case series
Patient 1 2 3 4
Age (yr)/sex 40/M 41/M 46/F 56/F
Presentation Acute right hypochondrial Nonfunctional large right- Solitary right functional Solitary left functional 
pain mimicking acute sided abdominal mass adrenal tumour adrenal tumour
abdomen
Tumour size 16.5 × 14.5 × 11.5 16 × 12 × 12 10 × 6 × 6 7 × 5 × 5
(cm)
Locally invasive Yes, to right lobe of liver Yes, to retrohepatic IVC No invasion past capsule No
and RA
Metastatic Yes, widespread, to the Yes, two solitary Yes, to pleura and Yes, tumour recurrence 
lungs, liver and bone pulmonary nodules paratracheal nodes in detected in contralateral 
right side of chest only adrenal 6 years later, 
and liver and lung meta-
stases 1 year later
Surgery Right hemihepatectomy Two-staged main tumour Initial right adrenalectomy, Left adrenalectomy 
and tumour debulking resection via laparotomy subsequent right repeated for the right 
followed by tumour thoracotomy and side, no surgery for 
thrombus excision via resection of metastatic metastases
median sternotomy nodules
Outcome of Pain and symptom Stormy postoperative Small amount of residual NA
surgery palliation course in ICU with ARF tumour
after first operation, 
died from MODS after 
second operation
Chemotherapy Given three courses, one Planned but not started, Patient declined Initial 11 cycles of CVD 
of CVD and two of patient died 4 days after and five cycles of 
paclitaxel second surgery paclitaxel with partial 
response, further 
chemotherapy with 
anzatax, navelbine, 
gemcitabine and 
doxorubicine with no 
response
Disease Yes, increase in size of NA No Yes, recurrence of 
progression metastases and pleural metastases and rise in 
effusion biochemical markers
Outcome Died from disease Died from MODS 4 days Alive 2 years after resection Alive 3 years after starting 
progression 1 year after after surgery of metastases and chemotherapy despite 
initial presentation 5 years after initial disease progression 
diagnosis and unresponsive to 
chemotherapy now
IVC = inferior vena cava; RA = right atrium; ICU = intensive care unit; ARF = acute renal failure; MODS = multiorgan dysfunction syndrome;
NA = not available; CVD = cyclophosphamide, vincristine and dacarbazine.
Results
Demographics
The four patients were generally young and in their forties,
with the oldest aged 56. There was an equal number of
men and women, of which two men were Malay and two
women were Chinese.
Mode of presentation
The mode of presentation was highly variable. Patient 1 pre-
sented with severe right hypochondrial pain associated with
fever and diaphoresis, mimicking an acute abdomen.
Computed tomography (CT) subsequently revealed a large
16.5 × 14.5 × 11.5 cm retroperitoneal tumour arising from
the right adrenal (Figure 1A). Subsequent biochemical data
confirmed the functional nature of the tumour giving rise
to some of the symptoms, namely elevated 24-hour urine
vanillylmandelic acid (VMA) of 210 μmol/day (0–34.3)
and markedly elevated levels of 24-hour urinary cate-
cholamines: epinephrine 2,857 nmol/day (0–1,709), nor-
epinephrine 2,190 nmol/day (89–473) and dopamine
10,495 nmol/day (424–2,612).
Patient 2 presented with a large right-sided abdominal
mass. He was otherwise asymptomatic. The 24-hour urinary
VMA was within the normal range at 27.3 μmol/day,
while the values for urinary normetanephrines and nor-
epinephrine were only mildly elevated at 2,803 nmol/day
(600–1,900) and 620 nmol/day (89–473), respectively.
Two patients presented with catecholamine excess
after resection of the primary phaeochromocytoma.
Patient 3, a 46-year-old woman, presented with symp-
toms of catecholamine excess 4 years after the initial surgery.
Her 24-hour urinary VMA was at the high-normal range at
1,664 μmol/day, but the urinary normetanephrines were
definitely raised at 12,328 nmol/day. What was thought
to be a local recurrence eventually proved to be metastatic
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Figure 1. (A) Computed tomography (CT) on the left shows post eventual debulking surgery performed for the large primary
retroperitoneal tumour that is shown at its largest diameter on the right. (B) Left: CT 1 month after right hemihepatectomy with
bilateral lobe liver metastases. Right: CT shows the largest liver metastasis before resection.
lesions in the right pleura and paratracheal nodes. This was
confirmed with meta-iodobenzylguanidine (MIBG) scans.
Patient 4, a 56-year-old woman, had a recurrence 
of symptoms of catecholamine excess attributed to
phaeochromocytoma in the right adrenal 6 years after 
initial resection of left phaeochromocytoma in 1995.
Metastatic lesions in the liver and lungs were detected on
MIBG scans 1 year after the second adrenalectomy when a
second repeat episode of her symptoms surfaced. She was
admitted with flash pulmonary oedema secondary to cate-
cholamine surge, which required her to be intubated and
ventilated in the ICU. Her 24-hour urinary normetanephrine
was found to be elevated at 7,700 μmol/day.
Tumour characteristics
The male patients had distinctly larger tumours of a size
that was clinically palpable. Patient 1 had metastatic nod-
ules in both lobes of the liver and lungs, as well as wide-
spread metastases to the ribs, lumbar vertebrae and pelvic
bone (Figure 1B). Patient 2 had locally invasive tumour to
the retrohepatic inferior vena cava (IVC) and right atrium
(RA) in addition to two small solitary pulmonary nodules.
Patients 3 and 4 had smaller but more biochemically
active tumours. Findings at initial presentation did not
demonstrate any capsular invasion. However, both patients
were later found to have lesions in other remote sites of
the body.
Operative procedures
Patient 1 was a case of unsuspected phaeochromocy-
toma at initial surgery. An emergency exploratory laparo-
tomy was performed on the night of his admission as his
presentation suggested a perforated gangrenous gallblad-
der empyema. However, a large retroperitoneal tumour
with seeding of both lobes of the liver was found and no
attempt at trial dissection was made. He subsequently
underwent elective palliative debulking surgery about 1
month later. Prazosin 1 mg tds and propranolol 20 mg bd
were used for preoperative α- and β-blockade. Surgery was
necessitated as the patient developed pain and distension
of the abdomen from the enlarging tumour and second-
ary to ascites. This limited his mobility and adversely
affected his quality of life. For lack of sufficient informa-
tion in the literature, it was also the consensus between
the surgeon and oncologist that debulking surgery may
offer the patient a less complicated chemotherapy course
and a better chance at prolonging survival. Debulking of
the primary right adrenal tumour with right hemihepatec-
tomy was performed (Figures 2 and 3). Intraoperatively,
the blood pressure surged to 220/120 mmHg when the
tumour was manipulated, requiring intravenous glyceryl
trinitrate, phentolamine, esmolol and labetalol for control.
Postoperatively, there was no problem with blood pressure
control and his recovery was uneventful. Histology con-
firmed metastatic phaeochromocytoma (Figure 4A–D).
Patient 2, after extensive discussion with the patient
following the diagnosis of metastatic phaeochromocy-
toma, underwent radical surgery combined with postop-
erative chemotherapy in view of his young age. This was
planned as a two-staged procedure to be performed at the
same sitting, beginning with primary tumour resection
via a midline laparotomy followed by excision of IVC and
RA tumour thrombus via a median sternotomy. However,
difficulties encountered during the first stage resulted in
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Figure 2. Operative picture of the right adrenal tumour. Figure 3. Operative picture of the right liver metastases.
a prolonged surgery time and haemodynamic instability.
The decision was made to abandon the second stage and
to perform the resection at a later date. The patient under-
went a stormy postoperative course in the ICU compli-
cated by coagulopathy and acute renal failure. The second
stage was eventually performed 1 month after the first. A
right atriotomy extending down to the IVC was required
to remove the tumour together with a part of the anterior
wall of the suprahepatic IVC. Unfortunately, he died 4
days after the second stage from systemic vasodilatory
shock complicated by acute renal failure and acute respi-
ratory distress syndrome.
Patient 3 had metastatic lesions isolated in the right
lung pleura and paratracheal nodes 4 years after initial
resection for functional right phaeochromocytoma.
Surgery was intended to achieve near complete resection
of tumour tissue and, hence, eradicate all the sequelae of
functional catecholamine-secreting tumour, with a view
to adjuvant chemotherapy postoperatively. This took place
in the form of a right thoracotomy, resection of paratra-
cheal mass and parietal pleural nodules, and segmental
resection of the 10th rib together with pleural metastases.
Patient 4 had symptomatic phaeochromocytoma, which
was found in her right adrenal gland 6 years after she had
a similar disease presentation in her left adrenal. She had
undergone adrenalectomy at each sitting with resolution
of her symptoms. Recurrence of her symptoms of catecho-
lamine excess 1 year later led to the discovery of lung and
liver metastatic deposits. Surgery was no longer feasible
and she agreed to go ahead with a chemotherapy regimen.
Chemotherapy
A baseline CT done 1 month after the debulking surgery
for patient 1 already showed interval increase in the size
of the lung, contralateral liver and bone metastases
(Figure 5). He was started on a combination regimen of
■ WAN et al ■
298 ASIAN JOURNAL OF SURGERY VOL 29 • NO 4 • OCTOBER 2006
A
C
B
D
Figure 4. (A, B) Gross specimens of the adrenal tumour. (C) Gross specimen of the resected right lobe of the liver. (D) Microscopy of
the liver metastases shows phaeochromocytoma.
cyclophosphamide, vincristine and dacarbazine (CVD).
This was converted to paclitaxel after a month when dis-
ease progression was noted on reimaging (Figure 6), based
on previous anecdotal positive experience with the drug.
Patient 2 succumbed to the disease soon after surgery,
and patient 3 declined chemotherapy for the small amount
of residual tumour that remained after resection.
Patient 4 initially demonstrated good radiological and
biochemical response to chemotherapy with dramatic
tumour shrinkage in the metastatic sites. She received 11
cycles of chemotherapy with CVD over 1 year. Repeat CT
scan showed resolution of multiple lung nodules and seg-
ment 4 liver metastasis. Her 24-hour urine normetane-
phrine also declined from 7,700 to 3,000 nmol/day. Her
symptoms such as flushing also improved. This was con-
tinued with a further five cycles of paclitaxel chemotherapy.
Repeat CT scans showed no relapse and the 24-hour urine
normetanephrines also decreased to 1,800 nmol/day. For
2 years from the start of chemotherapy, the disease
remained stable. However, disease progression was 
soon noted after that with a rise in 24-hour urinary
normetanephrine, recurrence of lung and liver metastases
and relapse of symptoms. She was administered further
separate cycles of chemotherapy with anzatax, navelbine,
gemcitabine and doxorubicin, but with no halt in disease
progression.
Outcome of intervention
Patient 1 had significant symptomatic relief from pain
and abdominal distension after debulking surgery for half
a year. There was, however, disease progression, with CT
evidence of interval increase in the size of the lung, con-
tralateral liver and bone metastases. There was no response
to two different courses of chemotherapy regimens.
■ METASTATIC MALIGNANT PHAEOCHROMOCYTOMA ■
ASIAN JOURNAL OF SURGERY VOL 29 • NO 4 • OCTOBER 2006 299
A B
Figure 5. Computed tomography (CT) shows (A) development of right pleural effusion and increase in size of rib metastases com-
pared to (B) CT 6 weeks prior, evident of progressive disease.
60.81 mm
43.79 mm4.35 mm
4.86 mm
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Figure 6. Computed tomography shows progressive disease with increase in size of liver metastases within a month despite debulking
surgery and chemotherapy.
Patient 2 succumbed from multiorgan dysfunction
syndrome after making a difficult recovery from surgery.
Patient 3 benefited from both biochemical and
tumour remission after an aggressive surgical approach
to clear an apparently unilateral spread of metastases.
Not only did subsequent serial CT scans show stable dis-
ease in the small residual right lung metastases, but she
also remained symptom-free and averted the need for
anticatecholamine drugs. She is well and enjoys a good
quality of life.
Patient 4 had initial chemosensitive disease with the
spread of the disease controlled with chemotherapy after
complete excision of localized disease in each adrenal at
two separate sittings. Unfortunately, she suffered from a
relapse 2 years later and further chemotherapy was unable
to halt disease progression.
Discussion
The clinical presentation of phaeochromocytoma can be
varied. Hypertension, palpitations, headaches, sweating,
weakness, lethargy, pallor, anxiety and depression have all
been reported as presenting symptoms.4,5 The nonspecific
symptoms make phaeochromocytoma an underdiag-
nosed condition. It is estimated that it is diagnosed dur-
ing life in less than half of the patients in whom it is
found at autopsy.6 Undiagnosed tumour formed 17% of
cases in an 18-year review in Hong Kong,7 and up to 75% in
a series from the Mayo clinic spanning more than 50 years.8
Thirteen of 17 deaths could be attributed at autopsy to
the tumour or its catecholamine effect in another study
looking at 46 cases over a 14-year period.9 The description
of patient 1 illustrates a case of unsuspected phaeochro-
mocytoma where the predominance of abdominal signs
was suggestive of peritonitis.
The diagnosis of malignancy is not clear-cut in
phaeochromocytoma. The occurrence of phaeochromo-
cytoma in sites normally devoid of chromaffin tissue,
direct tumour invasion and overt metastases is usually
definitive for malignant disease. However, on a cellular
level, the usual histological criteria of malignancy like
capsular invasion and mitotic figures are only poorly pre-
dictive of eventual biological behaviour. As such, some
large tumours with poor histological prognostic features
remain disease-free years after the primary resection, while
belated metastatic spread and recurrent disease in the
form of widespread metastases are well recognized in
apparently benign tumours at primary resection. This is
illustrated in the cases of patients 3 and 4.
Survival data in malignant phaeochromocytoma have
shown two subsets of patients. In the first subset, which
is approximately half of the patients, there is an aggres-
sive course and most die within 4–5 years. In the other
half, the course is more indolent and many survive for
years without any targeted treatment.10 There have been
sporadic reports of prolonged survival even in patients
with widely metastatic phaeochromocytoma.11–13 Brennan
and Keiser14 reported three cases of unresectable metasta-
tic disease with prolonged survival of 10–23 years with
antihormonal agents and without any form of chemother-
apy. Surgery, when performed at various points in their
clinical courses, was to control local complications of
metastatic disease and came in the form of cervical lamin-
ectomy, colostomy, femoral fracture stabilization, biliary
bypass and adhesiolysis.
Musholt15 in his review paper cites the uniformly poor
prognosis of patients with tumours left in situ as sufficient
justification for surgery as the treatment of choice even
for tumour debulking only. There is, however, no data to
show improved survival rates after tumour debulking to
substantiate this approach. In general, surgery, if under-
taken in metastatic cases, should be aimed primarily at
resolving the complications of tissue destruction or
obstruction by tumour masses. It is also indicated in
tumour debulking with palliative intent in cases of mas-
sive tumours causing visceral pain and distension as in
the case of patient 1. However, where radical surgery in
the form of near-total resection of tumour can be per-
formed with acceptable risks, it might be worthwhile con-
sidering in combination with chemotherapy postresection
for the minimal residual disease.
When resection is not possible, a variety of other thera-
peutic modalities have been attempted and these include
chemoirradiation, 131I-MIBG, octreotide therapy and
arterial embolization.
MIBG scans currently play an important role in 
diagnosis and follow-up of phaeochromocytomas, speci-
fically its usage in localization of disease where CT scans
have failed to detect small tumours. A sensitivity of
77–100% and, more significantly, a specificity of 95–100%
have been reported with MIBG scintigraphy.16 In our 
case series, it has been invaluable in the detection of 
sites of recurrence of phaeochromocytomas in patients 
3 and 4.
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In a therapeutic setting, the intense uptake and pro-
longed retention of tracer doses of 131I-MIBG by some 
unresectable phaeochromocytomas formed the basis of
attempts to deliver doses large enough to bring about
tumour shrinkage.17 The results are less encouraging, how-
ever, with therapeutic activity only in certain highly selected
malignant phaeochromocytomas. In their early study of 28
patients, Shapiro and Sisson recorded partial tumour and
hormonal responses in only eight cases, with stable disease
in 10 and disease progression in the other 10 patients.18 Five
of these 8 cases recurred later with three unresponsive to
further MIBG therapy. Since then, therapy with 131I-MIBG
has been administered at multiple centres worldwide. A
review in 1997 of 116 patients worldwide who had received
such treatment revealed less than encouraging numbers
overall: 76% symptomatic response, 45% hormonal response
and 30% partial tumour regression.19 There were only five
complete responses, all of whom had minimal soft tissue
metastases. Rose et al20 further used 2–3.5 times higher
doses of 131I-MIBG in their 12 subjects but yielded only two
metastatic cases with complete response, with high rates of
haematological toxicity in their patient cohort. Lam et al21
on the other hand advocate a regimen of multiple interme-
diate dosage for better tolerance and as a useful adjunct pro-
viding longstanding palliation in malignant cases; they were
able to demonstrate complete symptomatic and partial
tumour volume response in their two patients who have
survived 5 and 16 years, respectively. The optimal dose and
frequency, as well as tumour and patient selection criteria,
remain unknown at this stage.
Due to the resemblance to neuroblastomas, chemother-
apy using the CVD regimen can be used. Tumour responses
of up to 57% have been reported with minimal side effects,
mainly bone marrow toxicity and hypotension. However,
most responses are transient without clear effects on
long-term survival. This is also reflective of our experience
with patients 3 and 4. Presently, there is no evidence avail-
able that chemotherapy prolongs patient survival in
metastatic disease and should probably be reserved for
palliation in symptomatic patients.10
Our small case series illustrates the variable clinical
outcome of malignant phaeochromocytoma. Patients 1
and 2 demonstrated the more aggressive subtype while
patients 3 and 4 may represent the more indolent group.
Although noncurative in the metastatic setting, partial
tumour resection has contributed to palliation as was
seen in patients 1 and 3.
Conclusion
The single most critical element in the management of
phaeochromocytoma is probably to consider it in the dif-
ferential diagnosis when appropriate and to obtain a
screening test.13 Otherwise, surgery in an unprepared
patient with an unrecognized phaeochromocytoma can
lead to catastrophic cardiovascular complications and
mortality.8
From the oncological perspective, malignant phaeo-
chromocytoma is extremely rare and the suitable manage-
ment in metastatic disease remains unknown. The clinical
course of metastatic phaeochromocytoma is highly 
variable and an indolent course can be expected in half 
of the patients. However, it is impossible to predeter-
mine this, making management and prognostication 
difficult.
With malignant phaeochromocytoma, there is a place
for radical surgery to achieve tumour eradication or
symptom palliation provided it can be done with reason-
able risks, even in the metastatic setting. 
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